DRUGS & THERAPY PERSPECTIVES

Scope & Guideline

Fostering Excellence in Drug Research and Clinical Applications

Introduction

Delve into the academic richness of DRUGS & THERAPY PERSPECTIVES with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1172-0360
PublisherSPRINGERNATURE
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1993 to 2024
AbbreviationDRUGS THER PERSPECT / Drugs. Ther. Perspect.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal 'DRUGS & THERAPY PERSPECTIVES' focuses on providing comprehensive insights into the use and management of pharmacological therapies across a variety of medical conditions. Its primary aim is to enhance the understanding of drug therapies, their clinical implications, and the overall therapeutic landscape.
  1. Pharmacotherapy Profiles:
    The journal frequently publishes detailed profiles of existing and emerging pharmacotherapies, highlighting their efficacy, safety, and clinical applications across various diseases.
  2. Clinical Decision-Making:
    Research often emphasizes the role of clinical decision-making in pharmacotherapy, particularly in complex cases such as managing multiple comorbidities in older adults.
  3. Pharmacovigilance and Safety:
    A significant focus is placed on pharmacovigilance, with studies examining adverse drug reactions, medication errors, and the impact of clinical pharmacy services on patient safety.
  4. Emerging Therapies and Innovations:
    The journal covers new and innovative treatments, providing insights into their potential benefits and limitations, which is crucial for clinicians looking to implement cutting-edge therapies.
  5. Healthcare Policy and Access to Medicines:
    Research also addresses healthcare policy issues, including access to medications and the implications of health technology assessments on clinical practice.
Recent publications in 'DRUGS & THERAPY PERSPECTIVES' reveal a shift towards several trending and emerging themes that reflect current challenges and innovations in the field of pharmacotherapy. This section outlines these trends.
  1. Personalized Medicine:
    An increasing number of articles emphasize the importance of personalized medicine, tailoring pharmacotherapy to individual patient needs, particularly in complex cases or chronic conditions.
  2. Management of Chronic Conditions:
    There is a growing focus on the management of chronic conditions such as diabetes, hypertension, and mental health disorders, reflecting the need for more effective long-term treatment strategies.
  3. Pharmacogenomics:
    Research exploring pharmacogenomic approaches to optimizing drug therapy based on genetic profiles is on the rise, indicating a shift towards more precise prescribing practices.
  4. Telehealth and Digital Health Solutions:
    With the rise of telehealth, the journal is increasingly addressing the role of digital health solutions in managing therapy adherence and patient engagement.
  5. Comprehensive Safety Evaluations:
    There is a trend towards more comprehensive evaluations of drug safety, including monitoring long-term effects and interactions, especially in vulnerable populations such as the elderly.

Declining or Waning

While 'DRUGS & THERAPY PERSPECTIVES' continues to explore a broad range of therapeutic areas, certain themes appear to be declining in prominence over recent years. This section highlights these waning scopes.
  1. Traditional Pharmacotherapy:
    There has been a noticeable decrease in articles focusing solely on traditional pharmacotherapy approaches, as the journal shifts towards more innovative and personalized treatment strategies.
  2. Generalized Guidelines for Drug Use:
    Publications that offer generalized treatment guidelines without specific contexts or patient populations are becoming less frequent, reflecting a trend towards more individualized and nuanced approaches to therapy.
  3. Focus on Older Pharmacological Agents:
    Research pertaining to older pharmacological agents is diminishing, possibly as newer therapeutics gain traction and as the focus shifts towards novel treatments and their comparative efficacy.
  4. Single-Agent Therapy Studies:
    There is a waning interest in studies that examine the efficacy of single-agent therapies, with more emphasis now placed on combination therapies and multidisciplinary treatment approaches.

Similar Journals

Journal of Pharmacology & Pharmacotherapeutics

Illuminating the Future of Pharmacology and Patient Care
Publisher: SAGE PUBLICATIONS INCISSN: 0976-500XFrequency: 4 issues/year

Journal of Pharmacology & Pharmacotherapeutics is a vital academic resource published by SAGE Publications Inc., focusing on the diverse and evolving fields of pharmacology and pharmacotherapy. With an ISSN of 0976-500X and E-ISSN 0976-5018, this journal serves as a platform for rigorous research and innovative insights from 2010 to 2024, reflecting the latest advancements and challenges within the pharmacological landscape. Despite being placed in the Q4 quartile for both general pharmacology and medical pharmacology in 2023, it continues to be an essential resource for researchers, professionals, and students striving to understand the complexities of drug action, therapy optimization, and pharmaceutical sciences. The journal underscores the importance of disseminating critical findings to stimulate further research and collaborative dialogue. Although currently not open access, it can be accessed through leading academic databases, positioning itself as a significant entity in the medical and pharmacological research community.

Australian Prescriber

Advancing Evidence-Based Prescribing.
Publisher: Therapeutic Guidelines LtdISSN: 0312-8008Frequency: 6 issues/year

Australian Prescriber is a distinguished open-access journal published by Therapeutic Guidelines Ltd, aiming to advance the field of pharmacology and medical prescriptions. Since its inception in 1994, this journal has been dedicated to disseminating essential findings and insights related to therapeutic guidelines and pharmaceutical care, making it an invaluable resource for healthcare professionals and researchers alike. With an ISSN of 0312-8008 and an E-ISSN of 1839-3942, it caters to an audience that values evidence-based medicine, empowering practitioners with knowledge to enhance clinical practice. The journal currently holds a Q2 ranking in the Pharmacology (medical) category and is recognized in the 51st percentile among its peers, reflecting its significant contributions to the medical field. Available from 1995 to 2024, this journal not only serves as an academic platform but also a critical discussion forum for professionals keen on improving pharmacological practices in Australia and beyond.

Current Drug Safety

Elevating Standards in Drug Safety Evaluation
Publisher: BENTHAM SCIENCE PUBLISSN: 1574-8863Frequency: 3 issues/year

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Fostering knowledge in pharmacology for real-world impact.
Publisher: WILEY-HINDAWIISSN: 0269-4727Frequency: 1 issue/year

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.

PHARMACOTHERAPY

Fostering Excellence in Medical Pharmacology
Publisher: WILEYISSN: 0277-0008Frequency: 12 issues/year

PHARMACOTHERAPY, an esteemed journal published by WILEY, stands as a pivotal resource within the field of medical pharmacology. With its ISSN 0277-0008 and E-ISSN 1875-9114, this journal has been at the forefront of pharmacological research since its inception in 1981. Renowned for its rigorous peer-review process and impactful contributions, it currently holds a prestigious Q1 quartile ranking in the pharmacology category, underscoring its significance as a leading publication in the field. It ranks #40 out of 272 journals in Scopus, placing it in the top 15% percentile of its category. While not an open-access publication, PHARMACOTHERAPY remains committed to advancing knowledge and understanding in pharmacological sciences, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to improving therapeutic outcomes and drug utilization. Based in the United States, at 111 River St, Hoboken, NJ, the journal is poised to continue its impact through to 2024 and beyond, welcoming contributions that further the discourse in pharmacotherapy.

JOURNAL OF CLINICAL PHARMACOLOGY

Enhancing Therapeutic Strategies through Rigorous Research
Publisher: WILEYISSN: 0091-2700Frequency: 12 issues/year

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Connecting researchers and practitioners in pharmacology.
Publisher: DUSTRI-VERLAG DR KARL FEISTLEISSN: 0946-1965Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.

MEDICAL LETTER ON DRUGS AND THERAPEUTICS

Navigating the Complexities of Drug Therapy
Publisher: MED LETTER INCISSN: 0025-732XFrequency: 26 issues/year

MEDICAL LETTER ON DRUGS AND THERAPEUTICS is a pivotal resource for professionals in the fields of medicine and pharmacology, published by MED LETTER INC. Since its inception in 1965, this journal has been committed to elucidating the complexities of drug therapy and clinical therapeutics, offering readers evidence-based insights and critical evaluations of the latest medications and treatment protocols. With a quarterly ranking reflecting its stature—Q4 in Medicine (Miscellaneous) and Q3 in both Pharmacology and Pharmacology (Medical)—the journal maintains a specific niche ensuring readers are equipped with updated information that continues to influence healthcare practices. Although it does not operate under an open access model, the journal is accessible to institutions and professionals eager to stay at the forefront of medicinal advancements. The importance of this journal lies in its dedication to enhancing pharmacological knowledge, thus catering to the needs of researchers, healthcare providers, and students alike, making it an essential addition to the literature in therapeutic drug interventions.

PHARMAZIE

Bridging research and practice in pharmacology.
Publisher: AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBHISSN: 0031-7144Frequency: 12 issues/year

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Enhancing Understanding of Pharmacological Treatments and Toxicology
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.